Business Context and Reporting Period
This Form 8-K is a current report filed by Inmune Bio, Inc. on September 7, 2023. The company is incorporated in Nevada and its common stock trades on The NASDAQ Stock Market LLC under the symbol INMB. The registrant is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or quantitative financial data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document serves solely to announce upcoming corporate events.
Guidance, Outlook, and Management Commentary
Management has announced that RJ Tesi, M.D. (Chief Executive Officer) and David Moss (Chief Financial Officer) will present at the following conferences:
- H.C. Wainwright 25th Annual Global Investment Conference: September 11-13, 2023.
- Baird Global Healthcare Conference: September 12-13, 2023.
A press release detailing these events is attached as Exhibit 99.1. No specific guidance, risks, or contingencies are disclosed in this text.
Investor Verification Checklist
- Verify the date and time of the upcoming conference presentations to access management commentary.
- Review the attached press release (Exhibit 99.1) for any additional details on the presentation topics.
- Consult the company's most recent 10-Q or 10-K filing for actual financial metrics, as this 8-K contains none.